上海交大教授创立，in vivo CAR-T公司锋寻生物完成近6000万融资

Core Insights - Fengxun Biotechnology, a pioneer in in vivo CAR-T cell therapy, has completed seed and angel round financing, with investors including Hanyuan Asset, Junlian Capital, and others. The funds will accelerate the evolution of its core technology platform, team building, and clinical development of its first candidate product in hematological malignancies and autoimmune diseases [2][3]. Group 1: Technology and Development - Fengxun Biotechnology focuses on overcoming key technical barriers in in vivo CAR-T therapy, particularly in high-efficiency delivery. The company utilizes a multidimensional engineered viral vector modification and T cell-specific delivery platform to directly and efficiently transduce T cells in vivo, generating CAR-T cells [3]. - The company's first pipeline is based on clinically validated targets, with clinical trials (IIT) for hematological malignancies expected to commence in Q4 2025, while plans for autoimmune diseases and solid tumors are set to start in 2026 [3]. - The in vivo CAR-T technology was developed over several years in the laboratory of Professor Cai Yujia at Shanghai Jiao Tong University, which is one of the earliest labs to focus on in vivo CAR-T and gene therapy technologies based on lentiviral vectors [4]. Group 2: Market Recognition and Future Plans - Professor Cai Yujia, founder of Fengxun Biotechnology, stated that the multiple financings completed within a few months reflect strong market and investor recognition of the team's technical strength and development prospects in the in vivo CAR-T cell therapy field. This marks a critical step towards clinical translation of this transformative technology [5]. - Fengxun Biotechnology and its sister company, Benda Gene, will operate independently but plan to collaborate in various fields to accelerate the optimization of Fengxun's technology platform and pipeline advancement, aiming to overcome challenges in clinical translation and benefit global patients [5].